

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
BRUEMMENDORF ET AL.

APPLICATION NO: 10/583,107

FILED: 17 JULY 2007

FOR: COMBINATION OF (A) N-{5-[4-(4-METHYL-IPERAZINO-METHYL)-
BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRIDYL)-2-
PYRIMIDINE-AMINE AND (B) AT LEAST ONE HYPUSINATION
INHIBITOR AND THE USE THEREOF

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:


This paper is supplemental to the Information Disclosure Statement filed June 15, 2006. Since Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, no fees are believed to be required under 37 C.F.R. §1.97(b)(3). If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "George R. Dohmann", written over a horizontal line.

George R. Dohmann
Attorney for Applicants
Reg. No. 33,593

Novartis
Pharma Intellectual Property
One Health Plaza, Building 101
East Hanover, NJ 07936-1080
(862) 778-7824

Date: 4/14/09